Center for Cellular Immunotherapies logo` Center for Cellular Immunotherapies

Powell Lab

Publications

  1. Bowtell D, Böhm S, Ahmed A, Aspuria P-J, Bast RC Jr, Beral V, Berek JS, Birrer M, Blagden S, Bookman MA, Brenton J, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman D, Iwanicki M, Karlan B, Kaye A, Lengyel E, Levine DA, Lu K, McNeish I, Menon U, Narod S, Nelson BH, Nephew K, Pharoah P, Powell DJ Jr, Ramos P, Romero I, Scott C, Sood AK, Stronach EA, Balkwill F: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015.
  2. Gattinoni L*, Powell DJ*, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nature Reviews Immunology. 1;6(5):383-93, May 2006.
  3. Ye Q, Song D, Poussin M, Yamamoto T, Best A, Li C, Coukos C and Powell, DJ Jr.: CD137 accurately identifies and enriches for naturally-occurring tumor-reactive T cells in tumor. Clinical Cancer Research 20(1): 44-55, Jan 1 2014.
  4. Song, D., Ye, Q., Poussin, M., Harms, G.M., Figini, M., and Powell, D.J., Jr.: CD27 costimulation augments the survival and anti-tumor activity of redirected human T cells in vivo. Blood 119(3): 696-706, January 2012.
  5. Urbanska, K., Lanitis, E., Poussin, M., Lynn, R., Gavin, B.P., Kelderman, S., Yu, J., Scholler, N. and Powell, D.J., Jr.: A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor. Cancer Research 72(7): 1844-52, April 2012.
  6. Lanitis E., Smith J.B., Dangaj D., Flingai S., Poussin M., Xu S., Czerniecki B.J., Li Y.F., Robbins P.F. and Powell D.J. Jr.: A human ErbB2-specific TCR confers potent anti-tumor effector functions in genetically engineered primary cytotoxic lymphocytes. Human Gene Therapy 25(8): 730-9, Aug 2014.
  7. Lanitis, E., Dangaj1, D., Hagemann,I.S., Song, D. Best, A., Sandaltzopoulos, R., Coukos, G. and Powell Jr., D.J. : Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE 7(11): e49829, Nov 2012.
  8. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, and Powell DJ Jr.: Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo. Cancer Immunology Research 1(1), July 2013.
  9. Lanitis, E., Poussin, M., Hagemann, I.S., Coukos, G., Sandaltzopoulos, R., Scholler N. and Powell, D.J., Jr.: Redirected anti-tumor activity of primary human lymphocytes transduced with a fully-human anti-mesothelin chimeric receptor. Molecular Therapy 20(3): 633-43, March 2012.
  10. Kandalaft L.E.*, Powell D.J. Jr.*, Chiang C.L., Tanyi J., Kim S., Bosch M., Montone K., Mick R., Levine B.L., Torigian D.A., June C.H. and Coukos C. : Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2(1): e22664, January 2013.
  11. Ye, Q., Loisiou, M., Levine, B.L., Suhoski, M., Riley, J.L., June, C.H., Coukos, G. and Powell, D.J., Jr.: Engineered Artificial Antigen Presenting Cells Facilitate Direct and Efficient Expansion of Solid Tumor-Derived T lymphocytes.  Journal of Translational Medicine 9(131), August 2011.
  12. Lynn RC, Poussin M, Kalota A, Feng Y, Low PS, Dimitrov DS, Powell DJ Jr.: Targeting of folate receptor-beta on acute myeloid leukemia blasts with chimeric antigen receptor expressing T-cells. Blood 125(22): 3466-76, May 2015.

NCBI bibliography: http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/40991793/?sort=date&direction=descending

Back to top